KNSA vs VRTX: Which Stock is Better?
Side-by-side comparison of Kiniksa Pharmaceuticals International Plc and Vertex Pharmaceuticals Inc in 2026
KNSA
Kiniksa Pharmaceuticals International Plc
$47.30
VRTX
Vertex Pharmaceuticals Inc
$440.05
Key Metrics Comparison
| Metric | KNSA | VRTX | Winner |
|---|---|---|---|
| Market Cap | $3.60B | $110.97B | VRTX |
| P/E Ratio | 62.77 | 28.50 | VRTX |
| EPS (TTM) | $0.75 | $15.31 | VRTX |
| Revenue Growth | 0.7% | 0.1% | KNSA |
| Gross Margin | 54.7% | 53.7% | KNSA |
Analyze KNSA
Full quant analysis
Analyze VRTX
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is KNSA or VRTX a better investment?
Comparing KNSA and VRTX: Kiniksa Pharmaceuticals International Plc has a market cap of $3.60B while Vertex Pharmaceuticals Inc has $110.97B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between KNSA and VRTX?
KNSA (Kiniksa Pharmaceuticals International Plc) and VRTX (Vertex Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: KNSA or VRTX?
Based on P/E ratios, VRTX trades at a lower multiple (28.5x vs 62.8x).
Which is growing faster: KNSA or VRTX?
KNSA has higher revenue growth at 0.7% vs 0.1% for VRTX.
Which company is more profitable: KNSA or VRTX?
Kiniksa Pharmaceuticals International Plc (KNSA) has higher gross margins at 54.7% compared to 53.7% for VRTX.
Which is the larger company: KNSA or VRTX?
Vertex Pharmaceuticals Inc (VRTX) is larger with a market cap of $110.97B compared to $3.60B for KNSA.
Should I buy KNSA or VRTX in 2026?
Both KNSA and VRTX have investment merit. KNSA trades at $47.30 while VRTX trades at $440.05. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between KNSA and VRTX stock?
Key differences: Market Cap ($3.60B vs $110.97B), P/E Ratio (62.8x vs 28.5x), Revenue Growth (0.7% vs 0.1%), Gross Margin (54.7% vs 53.7%).